000756 新华制药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入4,357,549-6.06%8,754,7228,466,3108,100,8457,502,987
减:营业总成本4,159,525-4.24%8,390,2137,940,3087,530,9057,020,478
    其中:营业成本3,522,515-5.03%7,110,1806,424,7615,709,1425,465,656
               财务费用30,495208.72%34,57312,14116,35132,019
               资产减值损失(40,425)-19.61%(47,394)(51,614)(69,283)(43,526)
公允价值变动收益------------
投资收益7,36325.24%7,7659,8369,5838,365
    其中:对联营企业和合营企业的投资收益338-129.65%(539)1581,418447
营业利润175,660-33.52%363,985534,371534,582476,707
利润总额164,943-37.41%358,917533,653532,686471,774
减:所得税费用16,988-47.50%52,61346,93926,57945,665
净利润147,955-36.00%306,304486,715506,107426,110
减:非控股权益(1,173)-115.82%16,41516,6919,59515,047
股东净利润149,128-33.35%289,889470,024496,512411,063

市场价值指针
每股收益 (元) *0.210-34.38%0.4200.6900.7400.620
每股派息 (元) *----0.1500.2750.2500.200
每股净资产 (元) *7.5661.80%7.5517.3156.7496.162
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容